Clinical Trials Logo

Immune Thrombocytopenia clinical trials

View clinical trials related to Immune Thrombocytopenia.

Filter by:

NCT ID: NCT04588194 Recruiting - Clinical trials for Immune Thrombocytopenia

Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

Start date: November 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab, romiplostim and high-dose dexamethasone.

NCT ID: NCT04562766 Recruiting - Clinical trials for Immune Thrombocytopenia

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

LUNA 3
Start date: December 14, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind study of rilzabrutinib in participants with persistent or chronic ITP, with an average platelet count of <30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Participants will receive rilzabrutinib or placebo 400mg twice daily. For each participant, the study will last up to 60 weeks from the start of the Screening Period to the End of Study (EOS) visit. This includes Screening (up to 4 weeks) through a 12 to 24-week Blinded Treatment Period followed by a 28-week Open-Label Period. Followed by a 4-week post dose follow-up. For adult participants, the maximum duration of the long-term extension (LTE) period will be 12 months from the date of the last adult participant to enter the LTE. For pediatric participants, the maximum duration of the LTE period will be 12 months from the date of the last pediatric participant to enter the LTE.

NCT ID: NCT04518878 Recruiting - Clinical trials for Immune Thrombocytopenia

Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER)

Start date: August 31, 2020
Phase: Phase 1
Study type: Interventional

This is a prospective, single-arm study to investigate the efficacy and safety of the combination of fixed low-dose eltrombopag plus recombinant human thrombopoietin (rhTPO) as treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) patients during the COVID-19 pandemic.

NCT ID: NCT04516967 Active, not recruiting - Clinical trials for Immune Thrombocytopenia

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

Start date: March 5, 2021
Phase: Phase 3
Study type: Interventional

A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months

NCT ID: NCT04516837 Recruiting - Clinical trials for Immune Thrombocytopenia

Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)

Start date: August 31, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective, multicenter, randomized, open-label study to investigate the efficacy and safety of eltrombopag plus recombinant human thrombopoietin (rhTPO) versus eltrombopag as treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) during the COVID-19 pandemic.

NCT ID: NCT04481282 Recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Start date: July 8, 2020
Phase: Phase 2
Study type: Interventional

Single-arm, open-label, single center study to assess the efficacy and safety of terbutaline plus danazol in patients with corticosteroid resistant/relapsed ITP.

NCT ID: NCT04368598 Recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of High-dose Dexamethasone and Acetylcysteine as the Treatment of Newly-diagnosed ITP

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

A single-arm, open-label study to evaluate the efficacy and safety of Acetylcysteine plus high-dose Dexamethasone in adults newly diagnosed with primary immune thrombocytopenia (ITP).

NCT ID: NCT04320225 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

Connection Between Vitamin D Level and the Efficacy of Dexamethasone in Immune Thrombocytopenia

Start date: October 1, 2020
Phase:
Study type: Observational

The project was undertaking by Qilu Hospital of Shandong University in China. The objective is to find out if there is a connection between vitamin D level and the efficacy of dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).

NCT ID: NCT04311593 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura

Start date: May 2020
Phase:
Study type: Observational

In this study, we will focus on the independent prognostic relevance of the expressions of CD38, CD4, CD56, CD11b and CD19 markers in immune cells with platelet changes in patients with newly diagnosed and chronic ITP.

NCT ID: NCT04289207 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia

Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

In this study, we tried to demonstrate clinical benefit of additive danazol to romiplostim therapy in patients with eltrombopag-resistant immune thrombocytopenia